Santarus and Pharming Announce Submission to FDA

Specialty biopharmaceutical company Santarus, Inc. SNTS and biotech company Pharming Group NV PHARM today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RHUCIN for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE).